首页> 外文期刊>EBioMedicine >Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness
【24h】

Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness

机译:叶酸受体阳性循环肿瘤细胞在不确定性肺结节的临床管理中的价值:一种预测恶性程度和肿瘤侵袭性的非侵入性生物标志物

获取原文
           

摘要

Background Non-invasive lung adenocarcinoma could benefit from limited resection, nonetheless, there is a lack of method to determine preoperative tumour invasiveness. We aimed to investigate whether folate receptor-positive circulating tumour cells (FRsup+/sup-CTCs) in combination with maximum tumour diameter (MTD) determines, before surgery, the invasiveness of small-sized, indeterminate solitary pulmonary nodules (SPNs). Methods A total of 382 patients with suspicious lung adenocarcinoma on computed tomography who were expected to undergo lung resection were enrolled in this study at three participating institutes and randomly assigned into training and validation cohorts. Before surgery, 3?mL peripheral blood was collected from all participants. FRsup+/sup-CTCs were analyzed using immunomagnetic leukocyte depletion and quantitated by ligand-targeted PCR method. After surgery, the resected tissues were diagnosed by pathologists according to IASLC/ATS/ERS classification. Findings FRsup+/sup-CTC levels in the peripheral blood can differentiate benign from malignant nodules with a sensitivity of 78·6%–82·7% and a specificity of 68·8%–78·4%. Both FRsup+/sup-CTC and MTD are independent predictive indices of invasive tumours for lung adenocarcinoma ≤2?cm based on multivariate analyses. Further, FRsup+/sup-CTC count in combination with MTD can differentiate non-invasive cancers from invasive cancers with a sensitivity of 63·6%–81·8% and a specificity of 71·4%–89·7%. Interpretation Detection of FRsup+/sup-CTC is a reliable method to differentiate malignancy of indeterminate SPNs. Combining of FRsup+/sup-CTC count and MTD could possibly enhance preoperative determination of the invasiveness of lung nodules and guide surgeons to select limited lung resection and avoid overtreatment for patients with non-invasive lesions. Fund None.
机译:背景技术非侵入性肺腺癌可以从有限的切除术中受益,但是,缺乏确定术前肿瘤浸润性的方法。我们旨在研究叶酸受体阳性循环肿瘤细胞(FR + -CTCs)与最大肿瘤直径(MTD)的组合是否在手术前确定了小型,不确定的孤立性肺结节的侵袭性(SPN)。方法在三所参与研究的机构中,总共382例经计算机X线断层摄影检查可疑的肺腺癌患者参加了这项研究,并随机分为训练和验证队列。手术前,从所有参与者中收集3?mL外周血。 FR + -CTCs用免疫磁性白细胞耗竭法进行分析,并通过配体靶向PCR方法进行定量。手术后,病理学家根据IASLC / ATS / ERS分类对切除的组织进行了诊断。在外周血中发现FR + -CTC水平可以区分良性和恶性结节,敏感性为78·6%–82·7%,特异性为68·8%–78·4%。基于多变量分析,FR + -CTC和MTD均是≤2?cm肺腺癌浸润性肿瘤的独立预测指标。此外,FR + -CTC计数与MTD结合可以区分非侵袭性癌症和侵袭性癌症,敏感性为63·6%–81·8%,特异性为71·4%–89 ·7%。 FR + -CTC的解释检测是区分不确定SPN恶性肿瘤的可靠方法。 FR + -CTC计数和MTD的结合可能会增强术前对肺结节侵袭性的确定,并指导外科医生选择有限的肺切除术,并避免对非侵袭性病变患者进行过度治疗。无资金。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号